|
|
|
| home > news > detailed info |
|
|
 INDUSTRY NEWS AND PRESS RELEASES |
IPP and Arca announce pharmaceutical partnership to foster UK Covid-19 innovation |
 |
|
22 October 2020 - IPP and Arca announce a new pharmaceutical partnership during a time of unprecedented collaboration in the industry - all united to find a vaccine for Covid-19. Under the new distribution partnership, IPP will manage Arca’s UK portfolio.
Italy’s premier label producer, Arca Labeling and Marking, specialises in complete identification solutions for the pharmaceutical manufacturing industry: self-adhesive labeling machines and laser markers synonymous with productivity, reliability, safety and durability. Using Arca software, the state-of-the-art machines can be integrated with inhouse information systems (4.0) for printing automation, validation and traceability.
With years of pharmaceutical experience in the UK, IPP’s Managing Director Jack Daly knows the value Arca’s equipment will have in the UK market, “We are delighted to bring Arca’s identification solutions to the UK at this critical time for the industry.”
Arca Group’s Export Manager Simone Lombardo is optimistic about the announcement and IPP”s Customer Service Level Agreement structure stating, “We are pleased to partner with IPP when Arca’s product line can support unprecedented innovation in the UK’s fight against Covid-19. Furthermore, IPP’s Service Level Agreements (SLAs) ensure its customers receive exceptional service support.”
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Johnson & Johnson Initiates Second Global Phase 3 Clinical Trial of its Janssen COVID-19 Vaccine Candidate
The Phase 3 ENSEMBLE study (NCT04505722) of the single-dose regimen of JNJ-78436735, the investigational vaccine candidate for the prevention of COVID-19 being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, continues to enrol and vaccinate study participants. ENSEMBLE is proceeding to enrol up to 60,000 participants worldwide.1
More info >> |
|
 |
White Papers |
 |
|
pAVEway™ expression system for the efficient expression of therapeutic proteins
Fujifilm Diosynth Biotechnologies
One of the major bottlenecks in the production of biopharmaceuticals is
the efficient expression of therapeutic proteins in microbial or
mammalian cells. The Escherichia coli pAVEway™ expression system
described here has been developed to ensure high product titres and
efficient scale up to GMP manufacture, whilst minimising many common
issues seen in other expression systems, such as ‘leaky’ expression
(expression of recombinant protein in the absence of inducer).
More info >> |
|
 |
Industry Events |
 |
12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology
8-11 February 2021, Vienna, Austria
In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >> |
|
|
